Adjuvant Therapy Following Surgery for Primary Malignant Melanoma

作者: Allan W. Silberman , Donald L. Morton

DOI: 10.1007/978-1-4613-3900-7_10

关键词:

摘要: Adjuvant therapy following surgical resection of primary malignant tumors has become an important consideration in the treatment patients with cancer. Modern and radiotherapeutic techniques have markedly reduced incidence tumor recurrence regional sites; however, overall patient survival rates not changed significantly over past 20 years. This lack improvement does indicate failure modalities; rather, it emphasized need for systemic altered our view role surgery other local treatments cancer therapy.

参考文章(43)
Myron R. Blume, Ernest H. Rosenbaum, Richard J. Cohen, Jay Gershow, Alan B. Glassberg, Eileen Shepley, Adjuvant immunotherapy of high risk stage I melanoma with transfer factor Cancer. ,vol. 47, pp. 882- 888 ,(1981) , 10.1002/1097-0142(19810301)47:5<882::AID-CNCR2820470512>3.0.CO;2-E
E. CARMACK HOLMES, H. STEPHENS MOSELEY, DONALD L. MORTON, WALLACE CLARK, DAVID ROBINSON, MARSHALL M. URIST, A rational approach to the surgical management of melanoma. Annals of Surgery. ,vol. 186, pp. 481- 490 ,(1977) , 10.1097/00000658-197710000-00010
Carl M. Pinsky, Yashar Hirshaut, Harold J. Wanebo, Joseph G. Fortner, Valerie Miké, David Schottenfeld, Herbert F. Oettgen, Randomized trial of Bacillus Calmette-Guérin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma. Annals of the New York Academy of Sciences. ,vol. 277, pp. 187- 194 ,(1976) , 10.1111/J.1749-6632.1976.TB41697.X
S. E. Salmon, Stephen E Jones, Adjuvant Therapy of Cancer ,(1990)
A. H. G. Paterson, D. Willans, L. M. Jerry, T. A. McPherson, Malignant Melanoma (Stage 1): A Clinical Trial of Adjuvant BCG Immunotherapy Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II. ,vol. 68, pp. 387- 392 ,(1979) , 10.1007/978-3-642-81332-0_58
Edward T. Creagan, Roger E. Cupps, John C. Ivins, Douglas J. Pritchard, Franklin H. Sim, Edward H. Soule, Judith R. O'Fallon, Adjuvant radiation therapy for regional nodal metastases from malignant melanoma. A randomized, prospective study Cancer. ,vol. 42, pp. 2206- 2210 ,(1978) , 10.1002/1097-0142(197811)42:5<2206::AID-CNCR2820420518>3.0.CO;2-S
U. Veronesi, G. Beretta, Controlled Study for Prolonged Chemotherapy, Immunotherapy, and Chemotherapy Plus Immunotherapy as an Adjuvant to Surgery in Malignant Melanoma (Trial 6): Preliminary Report Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II. ,vol. 68, pp. 375- 379 ,(1979) , 10.1007/978-3-642-81332-0_56
J. Durand, J. DE Marsillac, R. L. Ikonopisov, B. Kiss, F. Lejeune, R. MacKie, G. Madej, H. Mulder, Z. Mechl, G. W. Milton, A. Morabito, H. Peter, J. Priario, E. Paul, P. Rumke, R. Sertoli, R. Tomin, U. Veronesi, J. Adamus, C. Aubert, E. Bajetta, G. Beretta, G. Bonadonna, R. Bufalino, N. Cascinelli, G. Cocconi, A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma The New England Journal of Medicine. ,vol. 307, pp. 913- 916 ,(1982) , 10.1056/NEJM198210073071503
Frank C. Sparks, Melvin J. Silverstein, John S. Hunt, Charles M. Haskell, Yosef H. Pilch, Donald L. Morton, Complications of BCG Immunotherapy in Patients with Cancer New England Journal of Medicine. ,vol. 289, pp. 827- 830 ,(1973) , 10.1056/NEJM197310182891603
Sydney E. Salmon, Anne W. Hamburger, Barbara Soehnlen, Brian G. M. Durie, David S. Alberts, Thomas E. Moon, Quantitation of Differential Sensitivity of Human-Tumor Stem Cells to Anticancer Drugs New England Journal of Medicine. ,vol. 298, pp. 1321- 1327 ,(1978) , 10.1056/NEJM197806152982401